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Currently the ﬁeld of epilepsy lacks peripheral blood-based biomarkers that could predict the onset or
progression of chronic seizures following an epileptogenic injury. Thiol/disulﬁde ratios have been shown
to provide a sensitive means of assessing the systemic redox potential in tissue and plasma. In this study,
we utilized a rapid, simple and reliable method for simultaneous determination of several thiol-con-
taining amino acids in plasma using HPLC with electrochemical detection in kainic acid (KA) and pilo-
carpine rat models of epilepsy. In contrast to GSH and GSSG levels, the levels of cysteine (Cys) were
decreased by 42% and 62% and cystine (Cyss) were increased by 46% and 23% in the plasma of KA- and
pilocarpine-injected rats, respectively after 48 h. In chronically epileptic rats, plasma cysteine was de-
creased by 40.4% and 37.7%, and plasma GSSG increased by 33.8% and 35.0% following KA and pilo-
carpine, respectively. Treatment of rats with a catalytic antioxidant, 60 min after KA or pilocarpine sig-
niﬁcant attenuated the decrease of plasma Cys/Cyss ratios at the 48 h time point in both models. These
observations suggest that the decreased cysteine and ratio of Cys/Cyss in plasma could potentially serve
as redox biomarkers in temporal lobe epilepsy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Peripheral biomarkers for epilepsy are notably absent from the
tools available to inform its diagnosis and/or treatment. Although
a few studies have suggested peripheral biomarkers in human
epilepsies, the ﬁeld lacks biomarkers that diagnose, predict,
identify drug response and guide clinical trials [2]. Importantly,
biomarkers of epileptogenesis are lacking. While it is recognized
that only a fraction of individuals go on to develop epilepsy after
severe brain injury, no tests are currently available to identify an
at-risk group after injury. Ideally, blood-derived biomarker
(s) collected in the phases immediately post-insult, epileptogenic
period and chronic epilepsy period could inform diagnosis and/or
treatment. Candidate biomarkers may be identiﬁed from knowl-
edge of the pathogenesis of epilepsy development. In particular,
processes such as inﬂammation, oxidative stress, gene regulation
and metabolic alterations which are known mediators of epi-
leptogenic insults may reveal key biomarker candidates [4,15].
There has been signiﬁcant progress in developing peripheral
biomarkers indicative of redox changes in various disease such as
atherosclerosis, cardiovascular diseases, chronic neurodegenerativeB.V. This is an open access article u
rd, Aurora, CO 80045, United
Patel).diseases [1,3]. Redox alterations have been shown to occur in animal
models of epilepsies and may contribute to seizure genesis, epi-
leptogenesis and comorbidities [17]. Thiol/disulﬁde ratios provide a
sensitive means of assessing the systemic redox potential of tissue
and plasma in health and disease [11]. Cysteine is an important
amino acid in proteins that undergoes reversible oxidation/reduction
under biologic conditions and has been shown to not only control
protein function, but also serve as a biomarker of oxidative damage.
The ratio of cysteine/cystine (Cys/Cyss) has been proposed to serve as
a biomarker of redox status of cells, tissues and plasma in animals
and humans (see review [3] ). We have previously shown that epi-
leptogenic injury causes oxidative damage and alterations in the
brain tissue glutathione redox couples. Speciﬁcally, we have shown
that the ratios of glutathione redox couple i.e. reduced glutathione:
glutathione disulﬁde (GSH: GSSG) and/or reduced coenzyme A
(CoASH) and its glutathione disulﬁde (CoASSG) i.e. CoASH: CoASSG
are decreased in the kainic acid (KA) and pilocarpine models of TLE
[10,14,18]. The goal of this study was to determine plasma thiol redox
status in two chemoconvulsant models of epilepsy.2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma Aldrich. Kainic acidnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Manganese (III) meso-tetrakis (di-N-ethylimidazole) porphyrin
designated as AEOL 10150 was provided by Aeolus Pharmaceu-
ticals through a research agreement with the University of
Colorado.
2.2. Kainic acid and pilocarpine treatment
Adult, male Sprague-Dawley rats (300 g), purchased from
Harlan Laboratories (Indianapolis, Indiana) were used in all ex-
periments. Upon arrival, rats were group housed on a 12/12 light/
dark cycle with ad libitum access to both food and ﬁltered water.
Animal studies were carried out according to the National Institute
of Health Guide for the Care and Use of Laboratory Animals. All
procedures were approved by the Institute Animal Care and
Committee (IACUC) at the University of Colorado Anschutz Medi-
cal Campus. After one week of acclimation, rats were treated with
kainic acid (11 mg/kg, s.c.) or pilocarpine (350 mg/kg, s.c.) to in-
duce SE. In pilocarpine treated rats were injected with scopola-
mine (1 mg/kg, i.p.) 30 min prior to pilocarpine to limit peripheral
cholinergic effects and diazepam (10 mg/kg, i.p.) 90 min after pi-
locarpine to terminate SE. All rats were visually monitored during
SE and behavioral seizures were scored using a modiﬁed Racine
scale [9]. Brieﬂy, seizures were scored on the following scale: P1-
freezing behavior, P2-head nodding, P3- unilateral forelimb clo-
nus, P4- bilateral forelimb clonus with rearing, and P5- bilateral
forelimb clonus with rearing, falling, and/or hindlimb clonus. Only
rats experiencing SE deﬁned as: at least P3 or higher seizures
followed by a period of continuous seizure activity for at least
90 min, were included in further analyses as SE is the best pre-
dictor for the development of chronic epilepsy. Animals were sa-
criﬁced at 48 h (acute seizures) or 12 weeks (spontaneous chronic
seizures) after initial treatment. In spontaneous chronic seizures
group, only the rats exhibiting P3 or higher chronic seizures by
video monitoring were used. In acute seizure group, some KA or
pilocarpine-treated rats were administered with AEOL 10,150
5 mg/kg, s.c. at 60 min after KA or pilocarpine and thereafter every
4 h until sacriﬁce. Rats injected with KA or pilocarpine that did not
reach behavioral P3 score were called “non-responders”.
2.3. Plasma preparation
Blood (0.5 ml) was drawn with a 23-gauge heparinized
needle and syringe. Add blood from the syringe into a tube con-
taining 10 μl heparin (100 units/ml in saline, heparin sodium salt,
sigma H3393). Invert tube gently (to avoid hemolysis) 2 times to
mix. The blood tubes were centrifuged at 13,000 rpm 4 °C for
5 min to remove RBCs as soon as possible. Transfer 100 or 200 μl
of supernatant (plasma) to a new tube with cold same volume 2%
PCA/0.2 M boric acid. Samples stored at 80 °C until assay.
2.4. Measurement thiols and disulﬁdes in plasma
The levels of cystine, cysteine, homocysteine, methionine,
glutathione, glutathione disulﬁde, ascorbic acid and tyrosine in
plasma were measured with an ESA (Chelmsford, MA) 5600 Cou-
lArray HPLC equipped with eight electrochemical cells following
the principle of company instruction (Dionex Application Brief
131) and method prescribed obviously [5] with some modiﬁcation.
Potentials of the electrochemical cells were set at 400/500/600/
650/700/750/800/850 mV vs. Pd. Analyte separation was con-
ducted on YMC-Pack ODS-A C-18 analytical column (Waters Inc.,
4.6 mm250 mm; 5 mm particle size). A two-component gradient
elution system was used with component A of the mobile phase
composed of 50 mM NaH2PO4 pH 2.7, 1.0 mM 1-octanesulfonic
acid and component B composed of 50 mM NaH2PO4 pH 2.7,1.0 mM 1-octanesulfonic acid and 50% methanol. 100% A is run at
0.4 ml /min from 0 to 10 min at initial time and a linear gradient to
100% A 0.6 ml/min is run over the period from 10 to 18 min From
18 to 20 min, the conditions are maintained at 100% A 0.6 ml/min
then is run a linear gradient to 92% A, 8% B 0.6 ml/min from 20 to
28 min and returned back 100% A 0.4 ml/min from 28 to 32 min
Equilibration time for the next run is 8 min The sample tubes
containing 1:1 ratio plasma and 2% PCA/0.2 M boric acid were
centrifuged at 13,000g, 4 °C for 10 min to pellet protein. An aliquot
(20 μl) of the supernatant was injected into the HPLC.
2.5. Statistical analyses
All data is expressed as mean7SEM. Statistical differences
were analyzed by one-way ANOVA with post hoc multiple com-
parison test (Tukey test) or Student's t-test (two-tailed). P values
less than 0.05 were considered statistically signiﬁcant. All analyses
were performed using GraphPad Prism 5 software.3. Results
HPLC coupled with electrochemical detection enables the si-
multaneous determination of most thiol-containing amino acids,
including cysteine, cystine, homocysteine, methionine as well as
GSH and GSSG, and ascorbate in plasma. Separation of all peaks
from biological samples and standards was achieved with distinct
retention times and potentials (channels). All peaks observed in
samples were additionally identiﬁed using known standards with
retention times and ratios of peak distribution in different chan-
nels. The variation of retention time and ratio of distribution in
different channels between standards and biological samples were
o4%. Reproducibility of the method was evaluated by making six
injections of different concentration standards (0.01–2 nmol) or
different volume plasma solution (1–100 μl) per day in a 5-day
period. Repeated regression analysis of the standard or samples of
cystine, methionine and GSH reached R¼0.99 and cysteine and
GSSG reached R¼0.97–0.98. Typical chromatographs were shown
in Figs. 1 and 2.
Evaluation of plasma cysteine and cystine 48 h after treatment
with chemoconvulsants revealed decreases of 42% and 62% in
cysteine levels and an increase of 46% and 23% in cystine levels in
KA- and pilocarpine-treated rats, respectively. Ratios of cysteine/
cystine (Cys/Cyss) were signiﬁcantly decreased by 60.6% after KA
and 69.5% after pilocarpine. However, the plasma levels of GSH
and GSSG were not signiﬁcantly altered in either model 48 h after
injection of KA or pilocarpine. To verify the role of oxidative stress
on altered cysteine and cystine levels, we determined the effect of
a catalytic antioxidant, AEOL10150. Treatment of rats with
AEOL10150 administered 60 min after KA or pilocarpine and every
4 h thereafter for 48 h abolished the decreased Cys/Cyss ratios.
(Fig. 3).
In chronically epileptic rats displaying spontaneous behavioral
seizures (12 week time point), the levels of plasma cysteine were
signiﬁcantly decreased by 40.4% and 37.7% after KA and pilo-
carpine administration, respectively. The levels of plasma cystine
showed mild and statistically insigniﬁcant increases of 17.1% and
6.3% after KA and pilocarpine administration, respectively. Inter-
estingly, GSSG levels were also increased by 33.8% and 35.0% in KA
and pilocarpine models, respectively. However, no changes in GSH
levels were observed (Fig. 4). Ratios of Cys/Cyss and GSH/GSSG
were signiﬁcantly decreased by 47.0% and 29.4% after KA and 41.2%
and 31.1% after pilocarpine, respectively.
In non-responders, no changes were observed the levels of
cysteine, cystine, GSH, or GSSG at 48 h or 12 weeks after injection
of KA or pilocarpine. Furthermore, no changes in the levels of
Fig. 1. The chromatograph of the standards from left to right: Cystine 1 nmol, Cysteine 0.4 nmol, homocysteine 0.4 nmol, Ascorbic acid (AA) 2 nmol, Methionine (Met)
1 nmol, GSH 0.4 nmol, Tyrosine 2 nmol and GSSG 0.2 nmol were loaded into the column. Channel 7 (blue) potential: 800 mv; Channel 4 (red) potential: 650 mv and Channel
2 (green) potential: 500 mv. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. The chromatograph of the plasma samples from left to right: Cystine, Cysteine, homocysteine, Ascorbic acid (AA), Methionine (Met), GSH, Tyrosine and GSSG. All of
the peaks in plasma samples were double identiﬁed by standards with retention time and ratio of peak distribution in different potentials (channels).
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served in either model at the 48 h or 12 week time point (data not
shown).4. Discussion
In this study, we report three major observations. 1) A HPLC
method with electrochemical detection protocol provides a rapid,
simple and reliable method that allows the simultaneous de-
termination several thiols and thiol-containing amino acids in
plasma. 2) The levels of cysteine and ratios of Cys/Cyss were sig-
niﬁcantly decreased at the 48 h and 12 week time points in the
plasma of rats administered KA or pilocarpine. 3) Antioxidant
treatment signiﬁcantly inhibited the depletion of Cys/Cyss at the
48 h time point in both the KA and pilocarpine models conﬁrmingthe role of oxidative stress.
Here we provide a simpler electrochemical detection method
involving sample pretreatment that overrides pH adjustment and
derivatization required for ﬂuorescence detection. Repeated re-
gression analysis of the standards and samples using this method
showed high correlations coupled with low variability. Further-
more, HPLC with ﬂuorescence detection method only measures
cysteine, cystine, GSH and GSSG, whereas electrochemical detec-
tion allows measurement of additional thiol containing amino
acids, such as homocysteine and methionine. Cysteine and me-
thionine are the only amino acids in proteins capable of under-
going reversible oxidation/reduction under biologic conditions [6].
The method was validated in this study for a simultaneous de-
termination of thiols containing amino acids in plasma.
GSH/GSSG and Cys/Cyss, the two major low-molecular-weight
thiol/disulﬁde couples in mammalian plasma, are not in redox
Fig. 3. The levels of cysteine, cystine, cysteine/cystine, GSH, GSSG and GSH/GSSG in the plasma of rats 48 h after KA or pilocarpine. Saline or AEOL10150 5 mg/kg (dissolved
in saline) was injected by s.c. route beginning 60 min after KA or pilocarpine and every 4 h thereafter until sacriﬁce. Bars represent meanþS.E.M. The control levels of
cysteine, cystine, GSH and GSSG in plasma at 48 h after saline treatment are as follows: 5.6670.31; 32.5271.16; 3.9170.11; 0.3870.03, mM. *po0.01 vs. control, #po0.05
vs. KAþsaline or pilocarpineþsaline group, one-way, ANOVA, n¼6 per group.
Fig. 4. The levels of cysteine, cystine, cysteine/cystine, GSH, GSSG and GSH/GSSG in the plasma of rats 12 weeks after KA or pilocarpine treatment. Bars represent meanþS.E.
M. The control levels of cysteine, cystine, GSH and GSSG in plasma at 12 weeks after saline treatment are as follows: 5.7070.38; 32.6171.69; 4.4570.30; 0.5470.03, mM.
*po0.01 vs. control group, t-test (two-tailed), n¼5–7 per group.
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oxidized than Eh of GSH/GSSG in plasma [6,8]. Human studies have
revealed that the plasma Eh of Cys/Cyss is more readily oxidized in
comparison to the plasma Eh of GSH/GSSG smoking, athero-
sclerosis, cardiovascular diseases and aging [1,12,3,7]. This is evi-
dent in our rats at 48 h time point after KA or pilocarpine-induced
SE which revealed signiﬁcant depletion cysteine, increased cystine
and decreased Cys/Cyss ratio, but not GSH, GSSG or GSH/GSSG
ratio in the plasma. In chronically epileptic rats (12 week time
point), although both Cys/Cyss and GSH/GSSG ratio were de-
creased, the Cys/Cyss ratio was decreased to a greater magnitude
than GSH/GSSG in both of models. Furthermore, regardless of the
time point or model, decreased cysteine levels dictated the in-
creased oxidative stress in plasma. The lack of changes in plasma
cysteine in the plasma in “non-responder animals” suggests that
oxidative stress occurs due to ongoing disease progression and is
consistent with our previous observations in hippocampal tissue
of “non-responder animals” [14].
The ability of the catalytic antioxidant AEOL10150 to prevent
changes in plasma cysteine, cystine, Cys/Cyss and GSSG suggests
role of oxidative stress in their depletion. AEOL10150 is known to
possess high superoxide dismutase (SOD), catalase activity and
lipid peroxidation inhibitory activities and achieves sufﬁcient
plasma levels to exert antioxidant effects in rats [13]. Previous
studies from our laboratory have demonstrated AEOL10150's efﬁ-
cacy against brain oxidative stress indices including decreased
GSH/GSSG and increased 3-nitrotyrosine in KA and pilocarpine TLE
rats models [14,16]. Taken together, these observations suggest
that the decreased cysteine and ratio of Cys/Cyss in plasma can
serve as sensitive biomarkers for oxidative damage in the KA and
pilocarpine models of TLE. Furthermore, they may serve as sur-
rogate biomarkers of disease progression, pharmacoresistance
and/or treatment response in epilepsy patients.Conﬂicts of interest
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